CA9 and renal cell carcinoma: More recently, antibodies directed against membrane carbonic anhydrase 9 (CA9/CAIX) and CD147 [a widely expressed membrane glycoprotein involved in matrix metalloproteinase induction, cell adhesion and T cell activation (26)] have been developed to increase the number of selected CTCs in RCC patients (Figure 1).